Watchlist
NAD+
Compounding status requires review
No FDA-approved product is recorded. This molecule classification does not establish permission to compound an individual preparation. The register holds no recorded programs for NAD+, and this page exists so that absence is a recorded statement rather than a gap in an index.
What we hold
- Recorded programs
- 0
- Status recorded
- August 2026
US molecule classifications were recorded on 2026-08-31. An approved classification means an FDA-approved product of that molecule is recorded; it does not mean a compounded preparation is approved. The compounding category is a historical classification, not permission to compound a particular preparation. Product-specific legal requirements and clinical suitability cannot be established from this classification alone.
If that changes
If a US telehealth company begins selling NAD+ through a lawful route, it gets an entry here on the same terms as every other program: the price with the company’s own sentence beside it, the page it was read from, the date, the pharmacy where one is named, and the terms it is sold on. Nothing is written up in advance.
We do not publish dosing, protocols, or claims about what any molecule does. This is a record of what is sold and at what price, not clinical guidance, and how entries are recorded sets out exactly what we will and will not put in one.